Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Smith & Nephew plc (NYSE:SNN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 34,883 shares of the medical equipment provider's stock, valued at approximately $857,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Principal Securities Inc. lifted its holdings in shares of Smith & Nephew by 87.6% during the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after purchasing an additional 691 shares in the last quarter. National Bank of Canada FI boosted its holdings in shares of Smith & Nephew by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock valued at $41,000 after acquiring an additional 446 shares during the last quarter. Hara Capital LLC grew its stake in shares of Smith & Nephew by 391.4% in the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock worth $60,000 after acquiring an additional 1,957 shares during the period. Quadrant Capital Group LLC raised its holdings in shares of Smith & Nephew by 37.4% during the fourth quarter. Quadrant Capital Group LLC now owns 7,431 shares of the medical equipment provider's stock valued at $183,000 after purchasing an additional 2,024 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in Smith & Nephew by 4.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,120 shares of the medical equipment provider's stock valued at $224,000 after purchasing an additional 399 shares during the period. Hedge funds and other institutional investors own 25.64% of the company's stock.
Wall Street Analysts Forecast Growth
SNN has been the subject of a number of research analyst reports. Hsbc Global Res downgraded shares of Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. UBS Group cut Smith & Nephew from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. HSBC downgraded Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Canaccord Genuity Group increased their price objective on shares of Smith & Nephew from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. Finally, Wall Street Zen upgraded shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. Six equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Smith & Nephew presently has an average rating of "Hold" and an average price target of $28.00.
Get Our Latest Stock Analysis on Smith & Nephew
Smith & Nephew Stock Performance
Smith & Nephew stock traded up $0.08 during mid-day trading on Wednesday, reaching $30.14. 718,625 shares of the company traded hands, compared to its average volume of 795,285. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. Smith & Nephew plc has a fifty-two week low of $23.69 and a fifty-two week high of $31.72. The firm's fifty day moving average is $27.70 and its two-hundred day moving average is $26.75. The company has a market capitalization of $13.20 billion, a price-to-earnings ratio of 13.95, a price-to-earnings-growth ratio of 1.26 and a beta of 0.68.
Smith & Nephew Profile
(
Free Report)
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Further Reading
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
